Mykronor (Noradrenaline Tartrate)

Norepinephrine, the active ingredient in Mykronor, is a sympathomimetic presented as an injection for intravenous use. It acts as a potent vasopressor to raise blood pressure in critically ill patients experiencing acute hypotension, septic shock, or cardiac arrest.

GNH USA supplies Mykronor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global healthcare facilities.

Mykronor is employed as a vasopressor in critical care settings to manage life‑threatening low‑blood‑pressure states.

Acute hypotension: rapidly increases systemic vascular resistance, helping to restore adequate arterial pressure and organ perfusion in patients with sudden drops in blood pressure. Septic shock: counteracts profound vasodilation, improving mean arterial pressure and supporting organ function during severe infection‑related circulatory failure. Cardiac arrest: provides essential support to coronary and cerebral perfusion during resuscitation, enhancing the chance of return of spontaneous circulation.

Adverse reactions may occur with norepinephrine administration.

Common Side Effects: - Headache: mild to moderate discomfort often related to rapid blood pressure changes. - Tachycardia: increased heart rate due to β1‑adrenergic stimulation. - Peripheral ischemia: reduced blood flow to extremities causing coldness or discoloration. - Nausea: gastrointestinal upset experienced by some patients.

Serious or Rare Side Effects: - Severe hypertension: excessive rise in blood pressure that can lead to vascular injury. - Myocardial ischemia: reduced coronary blood flow causing chest pain or infarction. - Tissue necrosis: local injury at infusion sites if extravasation occurs. - Anaphylaxis: rare allergic reaction requiring immediate intervention.

Use of Mykronor requires careful clinical monitoring and adherence to safety guidelines. - Monitor blood pressure continuously: adjust infusion rate to maintain target pressures. - Assess volume status before initiation: ensure adequate intravascular volume to avoid worsening hypoperfusion. - Use with caution in patients with cardiac disease: heightened risk of arrhythmias. - Avoid in patients with known hypersensitivity to norepinephrine or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Norepinephrine may interact with other cardiovascular agents, altering its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: can potentiate hypertensive crises. - Beta‑blockers: may blunt desired heart‑rate response. - Vasodilators (e.g., nitroglycerin): can counteract vasopressor effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance hypotensive episodes if volume is insufficient. - Diuretics: can exacerbate volume depletion, requiring careful fluid management.